Aug 20, 2024 / 09:00AM GMT
Walter Hess - DocMorris AG - CEO
Welcome, everybody, to our H1 2024 conference call. We are pleased to inform you about our half-year 2024 results and give insights in the development of our Rx business. Today with me is Marcel, our Group CFO.
I start the business update with an introduction of where we stand. The indicative outlook of March consisted of two components, the OTC and the Rx business. We are achieving the plans for the OTC business in terms of growth and breakeven. The assumptions for the Rx business were indicative as nobody could foresee how eRx develops this year.
The first half year was coined by two completely different quarters, a challenging one before CardLink was introduced in the quarter with encouraging growth the months following the launch of CardLink. The speed of the transition from pRx to eRx went faster than anybody could expect. Consequently, a high number of our existing pRx customers were not able to redeem their prescriptions anymore with us until CardLink went live mid of April. Missing the first four months leads to a relevant reduction of
Half Year 2024 DocMorris AG Earnings Call Transcript
Aug 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers